Drug Discovery World

APRIL 3, 2023

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. All drug development processes evaluate a drug’s pharmacokinetics (PK) to gather data about its absorption, distribution, metabolism, and excretion in the body.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

Roots Analysis

AUGUST 15, 2023

Overview of Cell Free Systems Cell-free systems are ­in-vitro platforms which allow occurrence of biochemical reactions in the absence of living cells. It is worth mentioning that the first reconstituted system, Protein Synthesis Using Recombinant Elements (PURE) , was developed in 2001.

Protein 52

Protein In-Vitro Production Reagent 52

Drug Discovery World

OCTOBER 13, 2022

Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery. There were 127 exhibitors, 180 posters, 40 technology speakers, 52 scientific speakers as well as a series of eight seminars focused on automation and technology which DDW organised and moderated in the dedicated Tech Theatre. .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

Drug Discovery World

FEBRUARY 15, 2023

Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6. Between 2017 and 2020, the number of IO therapies being developed has increased significantly from 2030 (for 265 targets) to 4,720 (for 504 targets).

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

FEBRUARY 27, 2023

which removes the mandatory requirement for animal testing in the development of drugs for toxicity where enhanced performance is proven using in vitro alternatives. The technology offers features for cell and gene therapy developers and manufacturers, such as end stage deployment at the clinic or hospital.

Drugs 52

Drugs Life Science Protein Scientist 52